Fri, Dec 26, 2014, 3:07 PM EST - U.S. Markets close in 53 mins.

Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • meh76_1999 meh76_1999 Jul 9, 2013 3:42 PM Flag

    Journal of Infectious Diseases - Oxford University Press

    Folks, this is an extremely prestigious place for INO to have the results of its study published

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Bashers will say it's Oxford, Mississippi ...Press. It's all about truthiness folks.

    • The best place possible to be published: "

      Published continuously since 1904, The Journal of Infectious Diseases (JID) is the premier global journal for original research on infectious diseases. The editors welcome Major Articles and Brief Reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. JID is an official publication of the Infectious Diseases Society of America."

    • no its not. i'm an academic and can get the entire publication. results look fairly good, but JID has an impact less than 6. not bad but nothing to rave about.

      Sentiment: Strong Buy

      • 2 Replies to skinny_carl
      • How bout Science Translational Medicine? Is that good enough for you? That is where the HPV vaccine data went.
        Its impact factor is 10.57.
        Proceedings of the National Academy of Science has an impact factor of 9.37. Would you call that a not so prestigious journal? INO has not published in PNAS, but the reason I bring it up is they published their data in a high impact Science press journal.
        Here's the deal about companies: With the exception of research institutes within biomed companies such as DNAX of Schering Plough, or Genentech, most biomed/biotech companies publish in middle of the road to low impact journals just because they want their data published with the least amount of headache
        Publishing in a journal like Science Translational Medicine is way more headache for a company. Usually instead of being reviewed once, they often go through multiple cycles of review because scientists are pi$$y people in general. If you are truly an academic, you would know how scientists are territorial, and to publish in an extremely high impact journal, you need to be politically connected to editors and other researchers.
        Now for the field of infectious diseases, the J Infect Dis is the top journal in that field. For the field of translational medicine, Science Translational Medicine is the 5th highest impact journal in the field behind Nature Medicine, Journal of Clinical Investigation, and Journal of Experimental Medicine, and PLOS Medicine. New Eng J Med is classified as a standard medicine journal, but they do have translational reports. It has the highest impact factor of any primary journal (meaning they publish primary research articles, review journals generally have higher impact factors because its easier to cite to a review article than 5 primary manuscripts to prove a point).
        Publishing in J Infect Dis, being the top infectious disease journal, means that the paper got through review by top ID docs, not a shabby feat. Get off your high horse academician

      • Oxford University Press = extremely prestigious

        regardless of JID impact factor

    • Yes Journal of infectious Diseases is a journal with high impact factor.

      Sentiment: Strong Buy

 
INO
9.295+0.185(+2.03%)3:07 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.